By: David Groberman
CEO & Founder
Share

HeraMED

HeraMED developed a unique, innovative product, that inspires confidence and peace of mind for pregnant women. Our solution, enables pregnancy monitoring and tracking the wellbeing of the fetus, in a reliable, simple and safe manner, anytime, anywhere.

280%

From Funding target

34

Investors

0

Days to go
Type:Equity   
Stage:Seed +
Category:Healthcare
•  Successfully funded    
•  15 days extension is activated     
  • Campaign Highlights
  • Pitch
  • Team
  • Investors 34
  • Updates

Campaign Highlights

Breakthrough Innovative Technology

Pregnancy is one of the most exciting, complex and lifechanging events for women and their families. Despite technological advancements that characterize the healthcare industry, pregnancy monitoring has remained nearly unchanged since the 60’s.
Monitoring is available only in medical facilities, and require operation by trained professional medical staff. For many women, even in developed countries, quick access to real time fetal monitoring may be challenging and expensive, while in other parts of the world – it is practically impossible.

HeraBEAT is the company’s debut product, combining breakthrough fetal monitoring technologies, at an accuracy level akin the professional gold-standard systems used in hospitals.

These technologies provide the pregnant mother and her family peace of mind throughout the pregnancy stages, and may allow for early detection of potential complications, at a family-affordable price, without leaving the house.

Market Potential

There are 140 million births in the world every year. The pregnancy market is estimated at hundreds of billons of dollars per year, with sharp growth of 15-20% YOY.

HeraMED’s innovative technology will be made accessible to every home, with vast potential to penetrate the market.

 

Joining the moment before takeoff

HeraMED’s technology has jumped over many meaningful hurdles, and is equipped today with Medical CE approval that allows it to market its products throughout the EU and in many other countries, such as: Canada, India, Hong-Kong, Singapore, Australia and South Africa.  

Additionally, the company received the Israeli Ministry of Health approval (‘AMAR’), that paves the way to market HeraBEAT in Israel.
HeraMED is preparing to obtain the FDA approval during 2018.
The company has completed extensive clinical trials and pilots that prove the technology is ripe and ready create a dramatic impact on the pregnancy market.

 

A winning team of doctors, pregnancy experts, technology and marketing power

HeraMED’s development team is comprised of serial entrepreneurs, leading engineers, technology and regulation experts, senior doctors, product development and manufacturing experts, and proven track record in business development and marketing. 

 

Groundbreaking product

In the modern world in general, and among millennials in particular, women are interested in taking ownership of the health of their pregnancy, and managing it on their terms. They wish to be involved and engaged, to bond with their baby and feel connected to their pregnancy, in a simple and convenient way, without wasting money or time running around, commuting, and waiting in line. HeraBEAT combines an advanced smartphone-based user-friendly UI, with a sleek ergonomic and compact design – allowing for an easy-to-use solution that is reliable, safe and affordable for women and their families.?

Pitch

The idea

The Problem

Pregnancy is one of the most prominent and meaningful events in life, with an unparalleled impact on the physical, emotional and socioeconomic health of women and their families. Monitoring the fetus’ physiological attributes is a genuine need throughout the pregnancy, and at times – crucial, in particular at the beginning and end stages of the pregnancy, as well as cases where the pregnancy is defined as a high-risk.
Despite technological advancements that characterize the medical ecosystem, existing solutions for pregnancy monitoring have remained nearly unchanged since the 60’s. Monitoring is available today primarily in medical facilities such as hospitals and clinics, and the pregnant mother is required to commute, wait in long lines, pay for the visit and service. Beyond this, in many locations women don’t have appropriate access to real-time fetal monitoring, which could result in complications and even tragedies.

 

The Solution

HeraMED developed a unique, innovative and revolutionary technology which allows a reliable, accurate and safe, home based pregnancy monitoring at a family affordable price. HeraBEAT is a comprehensive pregnancy monitoring solution which combines advanced sensing technologies with high-level quality design, safety and accuracy at the highest level of the medical requirements.

HeraBEAT was designed from the ground up to be used at home by the un-experienced expecting mother, thus requires no prior knowledge or training. The solution further integrates advanced Smartphone-based user interface with a straight forward, ergonomic and functional design.

HeraBEAT incorporates multiple unique and proprietary sensors developed in house by the company’s R&D team:

  • Innovative FHR transducer – accurately measures the Fetal Heart Rate (FHR) based on optimized and fine-tuned Ultrasound Doppler technology
  • An array of optical sensors (PPG) – for Maternal Heart Rate (MHR) measurement and to prevent any confusing or cross-talk between Maternal and Fetal Heartrate.
  • Motion detection sensors – measuring performance levels and providing real-time feedback and guidance for the user in a step-by-step approach.

 

How does it work?

The multi-sensor unit continuously measures the physio-logical signals extracted from the expecting mother’s abdomen and sends the data wirelessly to the native iOS or Android App. The software implements a unique signal processing algorithm that serves several goals:

  • Filtering and amplifying the Fetal Heart Rate signals.
  • Separation and cross-talk prevention of the Fetal and Maternal Heart Rate signals.
  • Neutralization, filtering and eliminating irrelevant abdominal and digestion or any other “noises”. 

The data is then transmitted via BLE – Bluetooth Low Energy to the smartphone where it is further analyzed, sorted and stored.

The unique user interface presents the results to the user in a simple and clear manner which gives a straight forward understanding regarding the wellbeing and status of the fetus.

The data can be digitally shared at the press of a button via a medical cloud (HIPAA compliant) with any authorized person or entity – a physician, a midwife or a call center (even a loved one or a family member) and immediately reflect the status of the fetus.

In cases of potential risk of fetal distress the expecting mother can receive an immediate and actionable response which might make the difference and may potentially save lives.

 

HeraMED submitted 13 patents to comprehensively protect the different aspects and innovation of our solutions.

 

The company holds a medical ISO 13485 quality system and HeraBEAT was approved by one of the strictest notified bodies BSI (British Standard Institute) as a Class IIa medical device.

These approvals and certifications allow HeraMED to market its products throughout the EU as well as additional geographies.

Additionally, the company received the Israeli Ministry of Health approval (‘AMAR’), for marketing HeraBEAT in Israel.
HeraMED is preparing to obtain the FDA approval during 2018.
The company has successfully completed extensive clinical trials and verified that the technology is ready to be launched to the market.

 

Team

David Groberman
CEO and Founder 
Biography
David been developing multi-disciplinary medical devices for the last 15 years. Prior to founding HeraMED, spent over 8 years as Co-Founder and CTO at Meytar R&D – one of the leading R&D service provider firms in Israel. Some of Meytar’s most prominent clients are GE Healthcare, Philips Healthcare, Bayer, Teva, ST Electronics, HP-Indigo, Orbotech, Stratasys (Objet), Mazor Robotics, Pluristem and many others. During that time, David gained extensive, hands-on knowledge and capabilities, leading some of the most challenging projects in the field of multi-disciplinary medical and high-tech devices, ranging from implants to invasive mechanical, electro-mechanical and opto-mechanical instruments, surgical apparatuses and applicators, monitoring, diagnosis and scanning equipment. David is an alumnus of the IDF elite computer science unit MAMRAM. David holds B.Sc. cum laude from the faculty of Mechanical and bio-medical engineering in TAU.

  • Founder
Dr. Yosef Tovbin
Chief Medical Advisor 
Biography
Dr. Tovbin is currently Head of Labor and Delivery Ward at Assaf Harofeh Medical center one f the largest hospitals in Israel with over 10K births a year; He is a specialist in obstetrics, gynecology, infertility and ultrasound. A member of the Israeli Society of Obstetrics and Gynecology, the Israeli Society of Ultrasound in Obstetrics and Gynecology and the International Society of Ultrasound in Obstetrics and Gynecology – ISUOG. Dr. Tovbin graduated from the Sackler Faculty of Medicine - TAU.

Michael Nenner
VP R&D
Biography
Michael brings a combination of professionalism and creativity. Coming from a diverse background of serving as a high ranked marine officer in the IDF’s navy submarine flotilla, and an arts and music enthusiasts as a professional drummer. During his service in the IDF Michael became an expert in advanced weapons technology and specifically focused in Sonar technology. Michael holds a B.Sc in Engineering at TAU, and has been working in R&D and management of Multi-Disciplinary medical and monitoring devices for 4 years before joining HeraMED.

Dganit Littinsky
Director of Regulation and Quality
Biography
Dganit has Over 14 years of experience in Regulatory Affairs and Quality Assurance in medical device companies. Expertise in ISO13485 and worldwide regulatory submissions including CE & FDA.Prior to joining HeraMED Ltd., Dganit served as VP RA & QA at Hip Hope Technologies Ltd., a company specializing in medical wearable protective devices for the elderly. and at Pollogen Ltd., a company specializing in medical and aesthetic devices for variable dermatological treatments. Dganit also held QA and RA management position at Radiancy. Dganit holds a B.Sc. in Materials science engineering, BGU.

Sivan Barnea
Chief Commercial Officer
Biography
Sivan is a seasoned Business and Marketing leader with proven track record of high impact negotiations of multi-million dollar deals and game-changing initiatives, collaborative vendor partner and customer management, strategy development, product management, leading new product roll out, generating revenue, and reducing costs. Known for unique blend of strategic thinking with knack for meticulous execution. Energetic, creative and passionate, with extensive work experience spanning B2B and B2C products and companies, in both large organizations and startups, complemented by an MBA from Kellogg and a BSc in engineering.

Prof. Shmuel Einav
Chief Scientific Advisor
Biography
Prof. Einav is a world-distinguished expert in the field of biomedical engineering and specifically cardiovascular circulatory system. He is currently a University Research Professor at the State University of New York at Stony Brook and the Co-Director of their Center of Excellence. He is best known for his studies on blood flow through heart valves, coronary circulation, blood-tissue interaction, and flow and turbulent characteristics in occluded arteries. Shmuel has been elected as a Fellow of the American Institute for Medical and Biological Engineering (AIMBE), the International Federation for Medical and Biological Engineering, European Alliance for Medical and Biological Engineering & Science, Biomedical Engineering Society and a Fellow of the American Society of Mechanical Engineers (ASME). Prof. Einav is also a Distinguished Scholar in Residence at Caltech – California Institute of Technology. During his tenure at Tel Aviv University, under his supervision, the Department of Biomedical Engineering was established, a Graduate Program in Biomedical Engineering was successfully implemented, and in 2001 the first class of Undergraduate Biomedical Engineering students began its studies. He is the Founding Director of the Slezak Super Center for Cardiac Research and Biomedical Engineering, the Founding Director of the Kodecz Center for Medical Engineering and Physical Sciences, the Founding Director of the Austrian Laboratory for Cardiovascular Flow Dynamics, and the Founding Director of the California Friends Laboratory for Biomedical Computing and Parallel Processing. Prof. Einav has published more than 130 scientific articles, reviews and invited chapters, and a multitude of abstracts in the biomedical engineering, fluid mechanics and medical fields. He is a member of the editorial board of three leading journals. He is the Principal Investigator in a number of research projects and grants, awarded from Israel, Europe and United States sources, including

  • Advisor
Ady Jakubovitz
VP Marketing and Sales
Biography
Experienced serial entrepreneur with a demonstrated history of working and leading sales and marketing tea. He was HP‘s country sales manager and served as Executive VP at Matrix a leading software integration house and iMER Co-founder and CEO. Skilled in Strategic planning, out-of-the-box approach, Entrepreneurship, and Business Development. Strong leadership personality. Ady graduated from Technion - Israel Institute of Technology.

Investors 34

Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
6
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
9
Investments
Anonymous Investor
0
Followers
5
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
4
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
1
Followers
13
Investments
Anonymous Investor
0
Followers
3
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
2
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
4
Investments
Anonymous Investor
2
Followers
11
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments
Anonymous Investor
0
Followers
1
Investments

Updates

Currently there are no updates in this pitch

The Deal

Documents

Disclosures

The financing rounds made through the ExitValley platform are in accordance with a model of statutory exemption from publishing a prospectus pursuant to sections 15A(A)(1) and 15A(A)(7) to the Israeli companies law - 1965.
Under our model, the disclosure of detailed information on the company and information about the investment in each round of financing are limited to not more than 35 investors which are not qualified investors and the round of financing in not in the format of an offering arrangement ("רכז הצעה") as defined in the securities law
Follow us